Roche Diagnostics Licenses the Technology used for the LightCycler System to BIOTECON
Roche Diagnostics and BIOTECON Diagnostics GmbH have entered into a licensing agreement concerning Roche's LightCycler system technology. Under the terms of the agreement, Roche grants a non-exclusive worldwide license to BIOTECON authorizing them to develop, produce, and sell kits in the food and GMO (Genetically Modified Organisms) analysis field that are designed for use on the Roche LightCycler Instrument. The agreement includes the use of Roche's melting curve analysis technology. Financial terms of the agreement were not disclosed.
"With the licensing of the LightCycler instrument technology, BIOTECON will enhance the technological development and broaden the spectrum of applications especially in the fields of food and cosmetics," states Dr. Manfred Baier, Head of Roche Applied Science, a business area of Roche Diagnostics.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
ImmunoGen, Inc. Announces Genentech's Renewal of Technology Access Agreement
Metabolium names chief operating officer and chief scientific director
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
Apitope Receives Orphan Designation in the European Union for ATX-F8-117 for the treatment of Haemophilia A
Amsterdam Molecular Therapeutics’ Glybera Significantly Reduces the Risk of Pancreatitis in LPLD Patients
Archimedes Pharma Enrols First Patient in Phase III Programme for Nasalfent in Cancer Pain
The virulence of the Toxoplasma parasite identified
